Knight Therapeutics Stock Earnings Reports

Knight reported record Q1 2026 results: revenues of $148 million (up ~69% YoY) and record adjusted EBITDA of $28 million. Growth drivers were incremental revenues from the Sumitomo and Paladin portfolios, strong performance of promoted products (multiple recent launches), and customer purchasing patterns. The company executed four launches in Q1 and has completed ~15 launches over the last two years; management expects roughly 10 launches in 2026. Regulatory progress included submissions for Niktimvo in Brazil and Minjuvi in Argentina and Mexico, and approval in Brazil for Minjuvi's follicular lymphoma indication. Knight withdrew the Health Canada New Drug Submission for Qelbree due to manufacturing changes by its partner and intends to resubmit later (resubmission expected to add the manufacturing data and other requested information, delaying launch ~1–2 years). Ambisome remains a significant sales contributor tied to a Ministry of Health contract in several markets, but management notes generics face manufacturing challenges and could eventually erode exclusivity once approved. Financially, adjusted gross margin improved to 48% and operating expenses rose to support the larger portfolio; adjusted EBITDA per share was $0.28. Cash and marketable securities were $127 million at quarter-end with approximately $58 million of debt; net cash improved to $69 million and leverage was under 0.7x. The company repurchased shares under its NCIB (2.0M bought to date, up to 4.2M remaining allowance through Aug 2026). Management increased 2026 guidance to $510–$525 million in revenues and expects adjusted EBITDA of ~15% of revenues, citing better promoted product performance and improved LatAm FX versus CAD. BD pipeline remains active with steady deal flow; management remains focused on disciplined, value-accretive in-licensing and acquisitions.